Asmaa M Zahran1, Helal F Hetta2,3, Shimaa Mansour1, Ereny S Saad4, Amal Rayan4. 1. Clinical Pathology Department, South Egypt Cancer Institute, Assiut University, Assiut, 71515, Egypt. 2. Department of Medical Microbiology and Immunology, Faculty of Medicine, Assiut University, Assiut, 71515, Egypt. hettahf@ucmail.uc.edu. 3. Department of Internal Medicine, University of Cincinnati College of Medicine, Cincinnati, OH, 45267-0595, USA. hettahf@ucmail.uc.edu. 4. Clinical Oncology Department, Faculty of Medicine, Assiut University, Assiut, 71515, Egypt.
Abstract
BACKGROUND AND AIM: Lung cancer is the number one cause of cancer-related deaths. Dendritic cells (DCs) are heterogeneous components of innate immunity that play a crucial role in the anti-tumor T cell immunity and may represent a promising approach for tumor immunotherapy. In this study, we aimed to evaluate the frequency of the two major subsets of DCs; plasmacytoid dendritic cells (pDCs) and monocytic dendritic cells (mDCs) in non-small cell lung cancer (NCSLC) and correlating them with different clinicopathologic features and survival outcomes. PATIENTS AND METHODS: This study was a case-controlled one, included 50 patients with denovo pathologically confirmed NSCLC and 20 healthy controls of comparable age and gender. After diagnosis and staging of patients, the frequency of DCs was evaluated using flow cytometry. RESULTS: We unveiled significantly reduced levels of pDCs (P = 0.024), and mDCs (P = 0.013) in NSCLC patients compared to controls. Furthermore, there was a significant accumulation of pDCs in non-metastatic patients compared to metastatic ones (P < 0.0001), while there was no significant (P = 0.6) differences in mDCs, and mDCs/pDCs ratio (P = 0.9). There was a Significant negative correlation (r = - 0.3, P = 0.04) between OS and mDCs. On the other hand, there was a significantly higher OS with pDCs ≥ 0.82 compared to patients with pDCs < 0.82, log rank Ch2 = 12.128, P < 0.0001. CONCLUSION: Despite the controversy about the prognostic role of pDCs not only in NSCLC but also in other solid tumors, our study sheds light on the possible prognostic impact of pDCs and mDCs on treatment outcomes of NSCLC patients.
BACKGROUND AND AIM: Lung cancer is the number one cause of cancer-related deaths. Dendritic cells (DCs) are heterogeneous components of innate immunity that play a crucial role in the anti-tumor T cell immunity and may represent a promising approach for tumor immunotherapy. In this study, we aimed to evaluate the frequency of the two major subsets of DCs; plasmacytoid dendritic cells (pDCs) and monocytic dendritic cells (mDCs) in non-small cell lung cancer (NCSLC) and correlating them with different clinicopathologic features and survival outcomes. PATIENTS AND METHODS: This study was a case-controlled one, included 50 patients with denovo pathologically confirmed NSCLC and 20 healthy controls of comparable age and gender. After diagnosis and staging of patients, the frequency of DCs was evaluated using flow cytometry. RESULTS: We unveiled significantly reduced levels of pDCs (P = 0.024), and mDCs (P = 0.013) in NSCLCpatients compared to controls. Furthermore, there was a significant accumulation of pDCs in non-metastatic patients compared to metastatic ones (P < 0.0001), while there was no significant (P = 0.6) differences in mDCs, and mDCs/pDCs ratio (P = 0.9). There was a Significant negative correlation (r = - 0.3, P = 0.04) between OS and mDCs. On the other hand, there was a significantly higher OS with pDCs ≥ 0.82 compared to patients with pDCs < 0.82, log rank Ch2 = 12.128, P < 0.0001. CONCLUSION: Despite the controversy about the prognostic role of pDCs not only in NSCLC but also in other solid tumors, our study sheds light on the possible prognostic impact of pDCs and mDCs on treatment outcomes of NSCLCpatients.
Authors: Helal Fouad Hetta; Asmaa Mohammad Zahran; Engy A Shafik; Reham I El-Mahdy; Nahed A Mohamed; Emad Eldin Nabil; Hend M Esmaeel; Ola A Alkady; Azza Elkady; Dina A Mohareb; Amal Hosni; Mohammed Mahmoud Mostafa; Abeer Elkady Journal: Microrna Date: 2019
Authors: Helal F Hetta; Asmaa M Zahran; Reham I El-Mahdy; Emad Eldin Nabil; Hend M Esmaeel; Ola A Elkady; Azza Elkady; Dina A Mohareb; Mohammed Mahmoud Mostafa; James John Journal: Asian Pac J Cancer Prev Date: 2019-06-01
Authors: Theresa L Murphy; Gary E Grajales-Reyes; Xiaodi Wu; Roxane Tussiwand; Carlos G Briseño; Arifumi Iwata; Nicole M Kretzer; Vivek Durai; Kenneth M Murphy Journal: Annu Rev Immunol Date: 2015-12-23 Impact factor: 28.527
Authors: Asmaa M Zahran; Helal F Hetta; Zeinab Albadry M Zahran; Alaa Rashad; Amal Rayan; Dalia O Mohamed; Zeinab Ahmed Abd Elhameed; Salah M Khallaf; Gaber El-Saber Batiha; Yasir Waheed; Khalid Muhammad; Hanaa Nafady-Hego Journal: J Immunol Res Date: 2021-10-11 Impact factor: 4.818